HMI-115

Drug / Medication

A monoclonal antibody targeting the prolactin receptor, currently in phase three trials, which may lead to less pain and disease progression in endometriosis without using hormones.

Mentioned in 1 video

Videos Mentioning HMI-115

397 - Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, & emerging treatments

397 - Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, & emerging treatments

Peter Attia MD

A monoclonal antibody targeting the prolactin receptor, currently in phase three trials, which may lead to less pain and disease progression in endometriosis without using hormones.